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Shaping stem cell therapies in Argentina: 





This paper aims to analyze innovation pathways for stem cell technology in Argentina. 
Firstly, we present a theoretical perspective on the co-construction of regulation 
and technology development, positing four main tensions that underlie regulatory 
building and the shaping of national strategies for regenerative medicine. Regulation 
is understood as a negotiated process among interests, values, benefits, rewards, and 
different understandings of safety, efficacy, access and availability. The framework is 
useful to explore how actors and their visions of desired futures shape the creation 
of standards and, in turn, how they configure the way these emerging technologies 
are produced, accessed and used. Secondly, we discuss in detail the Argentine case. 
We focus on (a) the deployment of state actions on capacity and regulatory building, 
(b) the creation of new businesses in response to patient expectations, particularly 
umbilical cord stem cell banks and the supply of experimental treatments, and 
(c) state-led actions to build a specific regulatory framework (still in the making). 
Ambiguities and gaps in the current legislation as well as scarce enforcement 
capabilities configure a legal “grey area” for for-profit experimental treatments. 
Building a specific regulatory framework is understood to be a part of Science, 
Technology and Innovation (STI) state agencies’ struggle to govern technology 
development in terms of national envisaged innovation strategies. Lastly, we show 
how STI authorities and scientists managed to align a broad coalition of actors that 
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encourage international harmonization strategies, following the pharmaceutical 
model of drug evaluation based on the multi-phase trial system.
Keywords: Stem cells, Regenerative medicine, Science Technology and Innovation 
Policies, Regulation, Technology governance.
La construcción de terapias con células madre en Argentina: 
regulación, gestión del riesgo y políticas de innovación
Resumen
Este artículo tiene como objetivo analizar las trayectorias de innovación en terapias 
con células madre en Argentina. En primer lugar, presentamos una perspectiva 
teórica sobre la co-construcción de la regulación y del desarrollo tecnológico, y 
planteamos cuatro tensiones principales que subyacen a la construcción regulatoria 
y a la conformación de estrategias nacionales para la medicina regenerativa. La 
regulación es entendida como un proceso de negociación entre intereses, valores, 
premios, beneficios y diferentes comprensiones sobre las nociones de seguridad, 
eficacia, acceso y disponibilidad. El marco conceptual es útil para explorar cómo 
los actores y sus visiones sobre futuros deseados moldean la creación de normativas 
y, a su vez, cómo éstas configuran la forma en que estas tecnologías emergentes 
se producen, se utilizan y cómo se accede a ellas. En segundo lugar, discutimos en 
detalle el caso argentino. Nos centramos en (a) el despliegue de acciones estatales 
para la construcción de capacidades científicas e institucionales, (b) la creación 
de nuevos negocios en respuesta a las expectativas de los pacientes, en particular 
bancos para la preservación de células madre de cordón umbilical y el suministro 
de tratamientos experimentales, y (c) las iniciativas impulsadas por el Estado para 
construir un marco regulatorio específico (aún en proceso). Las ambigüedades y 
los vacíos en la legislación actual, así como las escasas capacidades de aplicación, 
configuran un “zona gris” para los tratamientos experimentales con fines de lucro. 
La construcción de un marco regulatorio específico es entendida como parte de 
la búsqueda de las agencias estatales de Ciencia, Tecnología e Innovación (CTI) de 
gobernar el desarrollo tecnológico en términos de estrategias nacionales de innovación 
deseadas. Por último, mostramos cómo las autoridades de CTI y científicos lograron 
alinear una amplia coalición de actores que fomentan estrategias internacionales de 
armonización, siguiendo el modelo farmacéutico de evaluación de medicamentos 
basada en el sistema de ensayos clínicos multifase.
Palabras clave: Células madre, Medicina regenerativa, Políticas de ciencia, tecnología 
e innovación, Regulación, Gobernanza tecnológica.
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Introduction 
Throughout the past 20 years stem cell therapies have acquired a priority role in health research agendas worldwide. While the United States, the European Union, Israel and Japan have developed 
important R&D programs and specific regulatory frameworks on the subject, 
many developing countries like India, China, Brazil, Malaysia, Chile and 
Argentina, among others, have started to implement national strategies for 
the rapidly developing field of regenerative medicine, through capacity 
building programs and the effort to create specific regulations (Gottweis; 
Prainsack, 2006; Salter, 2008; McMahon; Thorsteinsdóttir; 2013; Palma 
et al., 2015; Sleeboom-Faulkner, 2016; Rosemann et al., 2016; Bin Abdul 
Aziz et al., 2018, among others).
Stem cells are non-specialized cells that can divide themselves, 
differentiate into other types of specialized cells, and self-renew in more 
stem cells identical to the first one. This opens a range of promises for 
research and clinical practice: scientists expect that by learning to control 
processes of cell culture, cloning, differentiation and reprogramming, it 
is possible to produce healthy cells and tissues to repair and/or replace 
functional or structural tissue or organ damage. Regenerative medicine 
comprises treatments in which stem cells are induced to differentiate into 
the specific cells required to repair such damages. 
Although the use of bone marrow, peripheral blood and umbilical 
cord stem cells for treating hematological diseases are common medical 
practices, the challenge in the past decade has been to use stem cells from 
these and other tissues to accomplish in vivo or in vitro differentiation in 
cells from other strains. In particular, the development of the Induced 
Pluripotent Stem Cells (IPSCs) technique by Shinya Yamanaka in 2006, 
which involves the ability to generate pluripotent stem cells from adult 
cells, opened a new set of potential opportunities for drug development, 
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disease modeling, and personalized medicine (Gottweis; Minger, 2008; 
Anastacia et al., 2010; Mikami, 2015)1.
The expectations built by scientists, public officials, the media, 
entrepreneurs and investors on stem cell development are anchored in 
their alleged “revolutionary applications”: their potential to transform 
healthcare ensuring cost-effective treatments for diseases with few present 
therapeutic alternatives, such as cancer, neurodegenerative diseases 
(Parkinson, Alzheimer), heart failure, diabetes, etc. (Singer, 2008; Mattis; 
Svendsen, 2011). 
So far, these expectations have had a positive economic correlation: 
different reports have estimated the worth of global stem cell market on 
5.17-12.04 billion USD in 2017 and a projected growth to 9.03 billion USD 
by 2023, with a compound annual growth rate of 9.74%-13.2% between 
2017 and 2023 (Research Market, 2018; Vision Gain, 2018). While the 
United States was identified as the market leader, the Asia-Pacific region 
is expected to record the highest annual growth rate during such period 
(11.6%). These studies show the significant increase in R&D funding for 
stem cell research and private investment (both business and venture 
capital) in the last 10 years.
In this scenario, scholars and policy makers have encouraged capacity 
building in regenerative medicine as an attractive alternative for developing 
countries, given the possibility of participating in this market since its early 
1 The possibility of reprogramming adult somatic cells into pluripotent stem cells (Induced 
Pluripotent Stem Cells or IPSCs) from mouse embryonic fibroblasts, reported by Takahashi 
and Yamanaka in 2006, was highly recognized by the community of stem cell scientists as 
an important achievement. IPSCs were seen as a promise to overcome some key issues 
in stem cell research: the ethical concerns related to the use of human embryonic stem 
cells and the difficulty of obtaining large numbers of adult stem cells. However, there is no 
consensus on whether ESCs and IPSCs can be treated interchangeably or on the therapeutic 
usefulness of IPSCs, which is yet to be confirmed. In many cases, IPSCs are used as tools for 
basic research or modeling diseases in a laboratory, rather than as sources for regenerative 
medicine (Anastacia et al., 2010; Mikami, 2015). The appearance of IPSCs has also raised 
questionings on the future of embryonic stem cell research (Gottweis; Minger, 2008).
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stages (Greenwood, 1998; Palma et al., 2015). These stakeholders assert 
that local innovation in this field may lead to more accessible treatments 
for the population – mainly on non-communicable diseases – and it may 
provide the technological and cognitive basis for the solution of domestic 
needs while contributing to health and economic development (Greenwood 
et al., 2006; McMahon; Thorsteinsdóttir, 2013).
Meanwhile, stem cell technologies have aroused heated debates 
– both in developed and developing countries – among policy makers, 
universities, scientists, companies, the pharmaceutical industry, private 
investors, bioethicists and patient groups (Salter, 2008; McMahon, 2014; 
Arzuaga, 2014; Luna; Salles, 2014; Palma et al., 2015; Sleebom-Faulkner, 
2016). At the same time, these technologies have raised hopes for novel 
treatments for a wide range of ailments, and expectations for new patentable 
and marketable developments. They have also stirred up the concern about 
these treatments’ effectiveness, safety and associated risks. 
In this scenario, Argentina has been no exception. Since 2006, the 
Argentine government has considered this technology a “main priority […] 
in terms of research and development” (Palma et al., 2015, p. 793). At a 
national level, it is possible to identify an effective capacity building program 
and state promotion efforts. Considered a “window of opportunity” for 
scientific, technological and economic development, Science, Technology 
and Innovation (STI) agencies have deployed several funding programs, 
regional networks and dedicated institutional support to create a specific 
regulatory framework (CONICET, 2012; MSTPI, 2012). 
However, at the same time, the construction of expectations on the 
potential therapeutic applications of this technology has increased. These 
expectations are usually disseminated by mass media, advertised by cord 
stem cell biobanks for autologous use2 and by clinics, which offer for-profit 
treatments that are not based on systematic clinical evidence. Hopes and 
2 Autologous use is the use of stem cells by the person from which they were obtained. 
Allogeneic use refers to the cases when the donor and recipient are different.
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possibilities for these technologies are exchanged in forums that bring 
together soon-to-be parents and patients with serious or incurable diseases 
(Krmpotic, 2011). In this scenario, for the past decade, scientists, STI agencies, 
bioethicists and patient organizations have warned against the risks of 
experimental treatments and the limitations of cryopreserving cord blood 
stem cells for autologous use. They have also started shaping a specific 
framework to regulate these emerging technologies and practices, setting 
standards in relation to quality, safety and effectiveness.
This paper aims to analyze the process of shaping innovation pathways 
for stem cell technology in Argentina. We explore how state policies 
define what constitutes a priority, a desired and acceptable direction for 
local regenerative medicine, deploying strategies that align diverse actors 
and materials (funding, capacity building, public advocacy actions, and 
regulatory initiatives) to establish certain technological development pathways 
(definitions, processes, legitimized actors and procedures) over others. 
We mainly address the agency of the regulation of technological 
development: how it incorporates visions on what are considered “good”, 
“desirable” and “possible” directions to be undertaken by the state, and 
how, in turn, it configures the way that actors produce, access and use 
new technologies. In other terms, we explore how regulation works 
within the process of technological development as a material matrix of 
sanctions and rewards, and how it is co-constructed along with public and/
or private investment decisions, capacity building strategies, innovation 
processes, market structures, infrastructures, production costs, access to 
goods and services, seeking to establish certain socio-technical dynamics 
(instead of others). In the stem cell case, we understand this process as 
a complex negotiation among heterogeneous actors (firms, scientists, 
regulation authorities, lobby groups, physicians, patients, investment groups, 
biobanks, health insurances, etc.), who weigh between risk management 
and expectations, interests and values, benefits and symbolic rewards, 
safety and efficacy, access and availability. 
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This research is based on a qualitative design of documentary analysis 
based on primary sources (news, institutional communications and press 
releases, websites, curriculum vitae, R&D projects, scientific papers, 
national STI plans, laws, ministerial resolutions, legislative projects, statistics, 
advertisements, etc.) and secondary sources (scientific papers, technology 
reports). The topic was surveilled between 2011 and 2018, using material 
retrieved from 2006 to date. Data gathering was conducted after a “follow 
the actors” strategy consisting of several nuclei: documents and material 
issued by the main national STI agencies (the ministry, the research council 
and the promotion agency), leading scientists, institutions and groups (their 
projects and trajectories), health regulatory agencies and regulatory key 
players, patient organizations, and private biobanks and clinics. Changes 
in the construction of stem cell expectations during the period 2006-2018 
were mapped following the media coverage on the matter: in the main 
national newspapers (La Nación, Página 12, Clarín, InfoBAE, Perfil) and local 
press (La Voz del Interior), STI national and regional news agencies (Agencia 
TSS, SciDev.Net, InfoTechnology, Apertura, Materia, NEXCiencia) and law 
portals (Diario Judicial, Microjuris). In addition, seven in-depth interviews 
were conducted with scientists, policy makers, regulators from different 
national agencies and members of patient organizations. 
The paper is structured as follows: in the next Section, we will address 
the main regulatory tensions around stem cells in a global scenario. Firstly, 
we explore the co-construction between the selection of STI policy priorities 
and the process of shaping technological regulations. Secondly, building 
on prior empirical works, we posit four tensions that cross the selection of 
regulatory pathways for stem cell technologies, as an essential feature in 
the adoption of national strategies. In the third Section we analyze how 
innovation trajectories for stem cells and regenerative medicine have taken 
place in Argentina for the past decade. To that end, we first examine the 
deployment of state actions on capacity building, orienting them towards 
expected innovation policy results. Then, in the next two subsections we 
discuss the creation of new business opportunities in response to patient 
expectations, particularly cord stem cell banks and the supply of experimental 
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treatments. Finally, we return to state led actions that attempt to build 
a regulatory framework to govern technology development in terms of 
national envisaged strategies. 
Regulatory tensions in a global scenario
Shaping regulation, shaping innovation
How do nation-states imagine their technological futures and define the 
orientation of desired Science, Technology and Innovation (STI) pathways? 
How does the construction of expectations about technologies (from 
scientists, patients, companies) intersect with policy decision making on 
technological development? What is the role of technology regulation on 
materializing visions on desired futures? 
Socio-technical imaginaries can be defined as “collectively imagined 
forms of social life and social order reflected in the design and fulfillment 
of nation-specific scientific and/or technological projects” (Jasanoff; Kim, 
2009, p. 120). They describe attainable futures, projecting visions on what 
is good, desirable and worthwhile to be undertaken by the state, linking the 
construction of expectations and risks with effective exercises of state capacity 
to influence technological development, in the selection of priorities and 
allocation of public expenditure. But imaginaries do not exist in a void. They 
work in a material matrix of sanctions and rewards that shape interrelations 
of domination and subordination, relative growth, reinforcement, relegation 
or decline (Therborn, 1989). These visions are built and reproduced through 
socio-technical coalitions of actors, institutions, technologies and resources 
(Thomas et al., 2017; Bortz, 2017). They influence the construction of 
technology and policy preferences, by inscribing these preferences into 
specific instruments, regulations and forms of intervention (“secondary 
beliefs”) (Sabatier; Weible, 2007). 
In turn, public policies constitute a central component of these 
material matrices in which these visions work: they shape technological 
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development, research and innovation trajectories towards those directions 
that are considered “good”, “desirable” and/or “possible (Therborn, 1989). 
Regulatory shaping, in particular, involves a power exercise, where a 
multiplicity of actors and elements (technologies, institutions, funding, 
guidelines, knowledge, ideas and beliefs) intervene, negotiating materials 
and technological practices, in the attempt to align them with desired paths 
of technological development and governance. These regulations, in turn, 
organize spaces, social relations and actors’ behaviors; condition structures 
of social distribution, production costs, access to goods and services; and 
generate incentives and restrictions through the distribution of benefits 
and sanctions, seeking to build irreversibility on the status quo (or revert 
it) (Akrich, 1992, Callon, 1992; Lascoumes; Le Gales, 2007; Thomas et 
al., 2017).
For the purpose of this paper, we will define “technology regulation” as 
the attempts made by state agencies “to shape the governance of technology 
in order to promote the public interest” (van Zwanenberg et al., 2011, p. 
12). This definition involves three main points: first, even when regulation 
is state-centered – given state capacity of legislation and enforcement – the 
state is not understood as a monolithic actor but rather as multiple actors 
with diverging interests. They negotiate regulatory frameworks with non-state 
actors (businesses, scientists, practitioners, citizens, NGO, lobby groups, 
media, among others). The latter are not considered as mere technology/
regulation users, but as a part of technology governance. 
Secondly, regulation is not only understood as an exercise of control 
on established technology products, processes and practices, but also as 
the aspiration to direct the development of new technologies. It seeks to 
ensure that technologies, and the social practices through which they are 
produced and used, follow one orientation instead of others, stabilizing 
them in that direction (van Zwanenberg et al., 2011). Third, regulations tend 
to be presented as serving “the public interest”, balancing private interests 
according to certain collectively agreed principles. Here, “public interest” 
is considered a contested political ground, whose definition results from 
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negotiations between diverse actors to impose their interpretations of what 
is “good”, “desirable” and “possible” (Therborn, 1989). 
Public policies are aimed at “providing”, “distributing” and “regulating” 
(Braithwaite et al., 2007). In the case of Science, Technology and Innovation 
(STI) policy subset, as regulations shape behavior, they also contribute to 
the ways in which technology development pathways unfold, sending 
signals (sanctions and rewards) about desirable/undesirable, acceptable/
unacceptable directions of technology development and use. At the same 
time, STI policies tend to be seen as “distributing” and “providing” activities 
(i.e. the distribution/provision of human resources training, subsidizing public, 
private and public-private projects, acquiring infrastructure). However, these 
capacity-building actions are “also regulating activities, to the extent that 
they might be designed to encourage public and private actors to create, 
modify, and diffuse certain kinds of technologies in relation to a broader set 
of policy objectives and ambitions” (van Zwanenberg et al., 2011, p. 13). 
Thus, technology regulation not only shapes the ways in which artefacts 
are used, how and to whom access is provided, but also may influence 
decisions on state innovation priorities, public and private investment, 
market structure, among others3.
In the case of stem cell therapy development, a key problem has 
been the inadequacy of existing regulatory frameworks (designed for the 
clinical testing and market approval of pharmaceutical drugs) in relation to 
the biological characteristics of stem cells. Regenerative medicine includes 
a range of techniques and technologies whose goal is to build or restore 
biological functionality within the body. Its distinguishing characteristics also 
diverge from molecular or biological drugs in that the aim of this therapy 
3 At the same time, as regulations provide signals about desired (and non-desired) 
technology development pathways, they cannot manage to impose them on their own. As 
van Zwanenberg et al. (2011) point out, many other “de facto” governance mechanisms 
shape technological practice, such as unintended regulatory effects, and the tendency of 
technology developers and users to reinterpret, evade and seek to shape regulatory norms 
into better alignment with their own private interests.
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is to not only heal but also to reconfigure the human body at the specific 
tissue and cell level (Webster et al., 2011, p. 402). 
Two main innovation pathways broadly characterize the stem cell 
research field at an international level: the first involves the development 
of cell therapy procedures on a patient-by-patient basis (such is the case of 
autologous use of bone marrow stem cells). The second one, following the 
pharmaceutical industry business model, seeks to develop a standardized 
product that can be used as a therapeutic by a large number of patients. 
The latter tends to use scaled-up allogenic tissue that has been substantially 
manipulated ex vivo to perform in specific ways (Webster et al., 2011). There, 
the primary regulatory concern around the development of new therapies 
is not so much about the origins of the cell (allogeneic or autologous) 
but about the degree of cell manipulation and whether it leads to a safe 
standardized product. Trialing stem cell treatments involves a particular 
set of problems, which diverge from biochemical/industrial drugs. For 
instance, the scarce knowledge about how regenerative tissues multiply and 
distribute around the body; how cells proliferate and behave beyond the 
local setting into which they are introduced; uncertainty about the effects 
of the administration route; or the oncogenic (cancer-causing) possibilities 
that different cell-handling procedures may entail (Webster et al., 2011).
In this scenario, state actors, scientists, health administrators and 
companies have agreed that specific procedures and risks for patients 
required new and suitable regulatory approaches. Moreover, the negotiation 
of regulatory frameworks for stem cell therapies has been marked by the 
widespread surfacing of experimental stem cells interventions on for-profit 
basis, provided outside multiphase randomized controlled trials (RCT) 
and exterior to the review of regulatory authorities. The provision of these 
for-profit therapies has evolved to a lucrative business and to a common 
practice in many countries (Sleeboom-Faulkner; Patra, 2008; McMahon, 
2014; Salter et al., 2015; Rosemann et al., 2016). 
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For these reasons, controversies on how appropriate regulation for 
stem cell-based treatments could look like have dealt with many issues. 
These converge under the broad umbrella of “risk” and “access” and range 
from discussions of ethical limits, to clinical methods, effectiveness, quality, 
safety concerns, the development of scientific standards that are considered 
“good”, “desirable” and “feasible” for human health application, to matters 
of intellectual property and the availability of new treatment options to 
patients (Rosemann et al., 2018). 
Four tensions for stem cell regulatory development
Building on previous empirical works, an international comparison 
of seven jurisdictions (United States of America, European Union, Japan, 
China, India, Argentina and Brazil) has indicated the emergence of a 
high level of variation in stem cell regulation (Rosemann et al., 2016). 
Regulatory developments in these jurisdictions unfolded between two 
central dynamics: attempts for harmonization vs. a process of regulatory 
diversification (Rosemann et al., 2016). 
Moves towards normative harmonization are oriented to international 
collaboration in R&D, trans-national clinical research and cross-border 
economic activities for the global market (Sleeboom-Faulkner et al., 2016). 
This trend, led by regulatory authorities in the United States and the European 
Union (EU), is exemplified by legislative instruments such as the Regulation 
for Human, Cellular and Tissue Products (HCT/Ps) in the USA, and the 
Advanced Therapy and Medicinal Products (ATMP) legislation in the EU 
(both in 2007), and the Guidelines for Stem Cell Research and Clinical 
Translation by the International Society for Stem Cell Research (2008). These 
harmonization processes have evolved from a pharmaceutical model of drug 
development and the ideal of evidence-based medicine (EBM), with the 
multiphase randomized controlled trial (RCT) system as the methodological 
gold standard. This tendency aimed to facilitate particular forms of global 
stem cell governance, framing the room for maneuver for national regulators, 
including capacity-building processes that may be required to adapt local 
capacities and processes to global standards.
Gabriela Bortz, Achim Rosemann & Federico Vasen
Sociologias, Porto Alegre, ano 21, n. 50, jan-abr 2019, p. 116-155.
128
On the other hand, there is an increase in the emergence of alter-
standardization politics that propose alternative methods and forms of 
evidence for clinical innovation in the stem cell field, to reduce the costs of 
clinical testing and to increase access to non-systematically proven innovative 
interventions at an earlier stage. Many of the regulatory impulses that shift 
away from RCTs have come from Asia, in countries such as Japan, India, 
China, and South Korea (Sleebom-Faulkner et al., 2016), but some of them 
have also started to be considered by the US or EU health authorities. As 
pointed out in earlier works, these clashes have resulted in four central 
dynamics of regulatory diversification (Rosemann et al., 2018): 
(a) A “cells-as-drugs” approach for stem cell treatments, which is based 
on the EBM/multi-phase trial system and follows from the Big Pharma model 
of drug evaluation (as described above).
(b) The emergence of a growing number of regulatory exceptions and 
exemptions, such as “hospital exemptions”, “compassionate use programs” 
or “fast track approvals”, adopted in the European Union and United States; 
(c) The flexible enforcement of regulatory standards, implicitly enabling 
the persisting supply of experimental for-profit interventions, outside the 
control of regulatory agencies. This trend has been prevalent in China and 
India but also observed in the United States; and 
(d) The abandonment of multi-phase randomized clinical trial systems, 
allowing the conditional, limited term market approval of stem cell products 
after early-phase clinical trials with a small number of patients, as has 
happened in Japan. The Japanese model is likely to influence regulatory 
schemes in other countries, or at least to result in the creation of additional 
types of regulatory exceptions for conditional market approval of stem cell 
therapies sidelining Phase I-III of clinical trials. 
The development and selection of regulatory alternatives for stem cells 
implies complex negotiation processes among stakeholders (firms, scientists, 
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regulation authorities, lobby groups, physicians, patients, investment groups, 
biobanks, health insurances, etc.). These different regulatory models weigh 
between diverse options that entail benefits, risks, interests and values in 
terms of economic competitiveness and business profit, safety and efficacy 
control, widening/restricting people’s access to healthcare goods and services 
(Vasen, 2008). 
In this context, four main tensions have been identified (Rosemann 
et al., 2018): 
(a) International integration and access to global markets vs. the 
facilitation of local innovation and business opportunities. Pressures for 
international regulatory harmonization arise from demands for participation 
in international research and global markets, mainly in developed countries. 
International harmonization of medicine regulation typically evolves around 
the use of multi-phase clinical trials, with the aim to achieve international 
safety standards, enabling the creation of new economic opportunities and 
possibilities for joint innovation, increased availability of health-related 
products and services, and the uncomplicated circulation of (biological) 
materials, patients and professionals. But, at the same time, it implies 
an increase of development costs for new drugs and biological products 
and it also tends to raise the entry barriers, especially for scientists and 
companies in developing countries and for small and medium companies 
more generally.  These can often not afford to comply with international 
regulatory requirements. 
For these reasons, national governments and regulatory bodies are 
confronted with a tension between aspirations to achieve access to global 
markets and international integration, and the facilitation of national home-
keeping strategies that allow for the development and protection of domestic 
market and innovation opportunities. This tension is particularly pronounced 
in low-to-middle income countries, where innovation strategies evolve 
in relation to locally available resources, local innovation ambitions and 
domestic health care priorities (Sleeboom-Faulkner et al., 2016). 
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(b) Rapid development of – and early access to – new medicines vs. 
the systematic testing of safety and efficacy. The second tension emerges 
from the demands from citizens and patients to obtain access to novel 
medical solutions and investigational products more rapidly and under a 
personal autonomy stance. This claim conflicts with the slow process of 
evidence-based drug development, which requires solid scientific evidence 
of efficacy and safety for their approval. In recent years, a growing movement 
has advocated for right-to-try medicine, which has resulted in regulatory 
adjustments and revisions (Salter et al., 2015). But acceleration of the drug 
development process has also been promoted by the pharmaceutical industry, 
which has lobbied for the adoption of fast track review and marketing 
approval mechanisms (Rosemann et al., 2018).  
(c) The realization of affordable medicines vs. the generation of corporate 
profits. The rising costs of drug development under evidence-based medicine 
standards and the pursuit of biotech and pharmaceutical companies to 
generate profits from newly developed drugs, comes into tension with the 
capacity of health insurance systems and individuals to afford and provide 
access to new treatments. This tension is especially significant in developing 
countries, but with growing inequalities, shrinking healthcare budgets and 
aging populations this is a problem also in high-income countries. At the 
same time, demands for more affordable drugs and the creation of regulatory 
alternatives (that lower the costs for drug development) conflict with the 
need to assure safe and efficient therapeutics. This tension challenges 
the assumption sustained by scholars and policy makers that stem cell 
innovation in developing countries will lead to more accessible treatments 
(Greenwood et al., 2006). 
(d) State led forms of regulatory control vs. deregulation demands. 
Regulatory frameworks for new medicines’ approval have been state-led, 
and co-produced with the pharmaceutical industry, establishing procedures 
that seek to protect the interests of drug producers and the safety of patients 
and trial participants. However, recent years have shown increased calls 
among both patients and corporations for deregulation, to facilitate broader 
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individual choice, more affordable drugs and the provision of (often non-
systematically proven or experimental) therapies that would not normally 
be permitted by drug regulatory authorities. This has aligned a new coalition 
of some patient organizations, researchers, free market health advocates, 
private clinics and small-to-mid-size biotech companies that seek to maximize 
experimental and clinical freedoms, and to minimize the regulatory controls 
and the costs for drug approval (Rosemann; Chaisinthop, 2016). In those 
cases, patients have become liable for the costs and consequences of these 
experimental treatments. 
As was stated afore, the ways in which governments and regulatory 
authorities respond to these tensions and conflicting regulatory choices 
are not only a matter of “control”, but they create different types of (state-
desired) futures for technological development, which affect issues such as, 
priority selection, allocation of public expenditure, capacity building, the 
construction of expectations, accessibility and risk management. 
The following section will explore how stem cell technology 
development has been configured in Argentina. This process will be 
addressed by reflecting on the tensions between (a) state capacity building 
strategies (under the assumption that they constitute an “opportunity” for 
technological development); (b) the emergence of new businesses and 
business opportunities (in part related to patients’ expectations); (c) and the 
configuration of a regulatory framework (still in the making) that responds 
to growing concerns about the risks of this new life technology.
Shaping stem cells innovation pathways in Argentina
Governing R&D capacities
In Argentina, Science, Technology and Innovation authorities have 
considered stem cell technology as one of the main “strategic socio-productive 
nuclei” within the health sector at the national STI plan (MSTPI, 2012). 
Since 2006-2007, it is possible to see the construction of this technology 
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as a “state priority in terms of research and development” (Palma et al., 
2015), based on a growing trend of institutional creation, funding programs, 
regional network generation, and attempts towards technology regulation. 
STI agencies, officers and key researchers signified technology investment 
in this early stage as a “window of opportunity” to bring the country closer 
to the “technological frontier”. 
The Ministry’s strategy on regenerative medicine and cell therapies is “to act 
as a bridge between basic research and clinical research, generating a strategic 
plan for development and investment in this subject”. […] The work in this 
area is of particular importance for Argentina […] “the issue is new, so we see 
that it is a great opportunity for the development of this branch of science in 
our country” (MSTPI, 2008, emphasis added).
The possibility of making a biotechnological platform to produce cells from 
reprogrammed cells is a golden opportunity (interview by CONICET with a 
stem cells leading scientist) (CONICET, 2012, emphasis added)
This meaning attribution is also reinforced in the description of funding 
instruments:
[...] oriented to provide reference infrastructure in state-of-the-art technologies 
and to generate capacities in fields of knowledge [...] in which current practical 
applicability is uncertain but that are vital to take advantage of new or possible 
‘windows of opportunity’ or to position themselves in the technological frontier 
(MSTPI, 2011, p. 20, emphasis added).
These actors considered its character as an emerging technology a 
privileged opportunity for playing science and technology catch-up: that 
is, to carry out learning processes and accumulation of knowledge and 
skills in advantageous conditions, at a time when entry barriers into R&D, 
production and design of new technologies are lower. It aims to achieve 
autonomous capacities and establishing R&D policies that may reduce the 
technological distance between developed and developing nations (Pérez, 
2001; Greenwood et al., 2006; Bortz et al., 2018). 
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Under that vision, the first specific policy action towards stem cell 
promotion was the creation of the Advisory Committee on Cell Therapies 
and Regenerative Medicine (ACCTRM) in 2006, organized by the president 
of the National Agency for the Promotion of Science and Technology, then 
transferred to the Ministry of Science, Technology and Productive Innovation 
(MSTPI) in 20074. The committee is composed by 16 members, including 
biologists, medical doctors, bioethicists, lawyers, and regulators. It aims to 
advise the government and general public on bioethical, legal, and scientific 
issues related to regulation, promotion and dissemination of research 
and clinical therapies involving stem cells. Also, it plays a leading role in 
Argentina towards advocating against non-authorized stem cell treatments 
and advising on the development of a legal framework.
Given that orientation, one of the main courses of state action in 
recent years has been aligning public investment for capacity building 
through a set of specific promotion and funding instruments. Among them: 
financing a stem cell research consortium (CICEMA, in 2008), composed 
of 10 institutions including basic, translational and clinical research groups, 
a technological linkage unit, foundations and private companies5; and 
financing the Human Reprogrammed Stem Cell Platform (PLACEMA, in 
2011), aimed at building capacities in reprogrammed stem cells and cellular 
differentiation, oriented in turn towards its potential clinical application 
and transfer to industry6. 
4 In September 2018 the MSTPI was downgraded to a Secretariat within the Ministry of 
Education, Culture, Science and Technology. Documentation on the ACCTRM has not 
changed since that process to the moment of witting this document.
5 The project was financed through the Strategic Action Program (PAE 37075): “Cross-
sectional and multidisciplinary study on the therapeutic use of genetically modified stem 
cells” (2006-2010). This first specific funding for stem cells involved funding of 2.5 million 
U.S. dollars allocated by the National Agency of Scientific and Technological Promotion 
(ANPCyT) to a consortium of ten public and private institutions (research institutions, 
medical centers and biotech companies).
6 The Human Reprogrammed Stem Cell Platform (PLACEMA) seeks to develop and provide 
reprogramming and cellular differentiation services to R&D groups and the pharmaceutical 
industry.
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In terms of international cooperation, in 2008 a binational agreement 
with Brazil was established (PROBITEC, in 2008) to train human resources 
and assign specific funding for basic, translational and clinical research 
(2011)7. This initiative emerged from an international symposium co-
organized between the MSTIP with the International Society for Stem Cell 
Research (ISSCR), gathering scientists from United States, Europe and Latin 
American (Pitossi; Podhajcer, 2014). 
As regards human resources training, since 2012 regenerative medicine 
also became a priority window for fellowship calls and accessing research 
tenure track at the national science and technology council. 
These efforts have resulted in a process of building endogenous R&D 
capabilities. In institutional terms, these have converged especially in around 
ten R&D units, which are national referents in the field since the early 
20008, mainly concentrated around the Buenos Aires Metropolitan Area. 
These centers and research institutes are presented – for the moment – as 
the main stem cells research, development and innovation loci, and also 
of human resources’ training. Since 2011, capacity building on stem cells 
has also spread into new institutions9 in the Buenos Aires Metropolitan 
Area, to other regions in the Buenos Aires province, to other big Argentine 
provinces, such as Córdoba, Santa Fe, and, more incipiently, in Mendoza, 
Neuquén and Tucumán.
7 Under this initiative, the ANPCyT issued in 2011 two competitive funding calls for research 
projects: the first one, aimed at basic and translational research, and the second one oriented 
to clinical stem cells’ applications, giving priority to research on cardiovascular, autoimmune, 
bone, cartilage, diabetes and cancer diseases.
8 Fundación Instituto Leloir, Fundación FLENI, Hospital Italiano, Universidad de Buenos Aires 
(School of Exact and Natural Sciences, School of Medicine and School of Pharmacy and 
Biochemistry), Hospital Garrahan, Fundación Favaloro, Universidad Austral, Instituto de 
Biología y Medicina Experimental (IBYME-CONICET), Fundación Pablo Cassará.
9 In Buenos Aires City and Province, institutes such as Universidad Nacional de San Martín, 
Instituto de Investigación en Biomedicina de Buenos Aires–CONICET–Max Planck, 
Universidad Nacional de Mar del Plata and Instituto de Investigaciones Bioquímicas de 
Bahía Blanca. In Córdoba, Universidad Nacional de Córdoba, and in Santa Fe province the 
Universidad Nacional de Rosario and Instituto de Biología Molecular y Celular de Rosario.
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In terms of funding, public support resulted in growth: from 18 projects 
funded in 2008, to 47 in 2012 (Pitossi; Podhajcer, 2014; Palma et al., 
2015) and over 100 in 2018 (SICYTAR, 2018). Currently, 88% of assigned 
projects have been concentrated between Buenos Aires city and Buenos 
Aires province, 5% in Córdoba, 3.4% in Santa Fe. The process of capacity 
building within these years has resulted in an estimate of over 400 researchers 
(tenured researchers, postdoc, PhD and fellows) who have received training 
in this technology (SICYTAR, 2018). 
Among the main research lines are cell differentiation and reprogramming, 
improvement of culture media for stem cell proliferation and preservation, 
with a convergent focus on neuroscience (especially neurodegenerative 
diseases), oncology, cardiology (including Chagas disease), metabolic diseases 
(such as diabetes), dermatology, ophthalmology, among others. Studies 
have been conducted mainly on hematopoietic, mesenquimal and neural 
cells, and over 50 researchers were registered to be working on induced 
pluripotent stem cells (SICYTAR, 2018). At least four groups have worked 
articulating stem cells with gene editing techniques.
In general terms, most of them fall firstly, within the scope of basic 
research and, secondly, in pre-clinical research. Four clinical trials were 
registered: the first one, carried out in 2005, for the treatment of chagasic 
cardiomyopathy with autologous cells. Since 2012, three other Phase I 
trial protocols were approved: studies on the effects of adult stem cells 
(hematopoietic precursors) on stroke patients; efficacy of autologous donation 
for the treatment of cartilage lesions; use of mesenchymal stem cells for 
skin regeneration in patients with severe burn injuries. These are carried 
out through partnerships between R&D institutes, private companies and 
hospitals.
Researchers from the above-mentioned main R&D units have been 
important advocators of state support to this field, in a process of co-
production of institutional, regulatory and funding initiatives. 
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However, the growing scientific interest in stem cells and the exponential 
process of capacity building in the last decade, has not correlated with the 
research activities of technology-based companies. STI policy makers argue 
that this disinterest from local industry is due to the need for additional 
hospital infrastructure and the uncertainty regarding return of investment. 
To date, most of stem cell-related R&D work has been carried out in 
research institutes and centers, mostly with state funding. In the few cases 
of company participation, the focus has mainly been on partnerships with 
public institutions.
Diverse actors assess that factors that may affect negatively on private 
sector participation are, firstly, the problem of defining the character of 
cells and stem cells as a product or as a procedure. This influences the 
possibility of scaled production and, consequently, the likelihood of obtaining 
returns from the high R&D investment. Secondly, the high costs involved 
in conducting multiphase clinical trials. Third, the lack of an established 
regulatory framework for stem cells (i.e. the lack of “good practices” for 
research and therapy provision) and of the intellectual property mechanisms. 
This generates an uncertain picture concerning the possibilities and ways of 
economic and/or social appropriation of these developments. This situation 
may also be related to a general tendency in Argentina of low private sector 
participation in innovation activities (16.4%), which is even lower than the 
Latin American average10 (RICYT, 2017). 
Cord cell banks: promises in the face of anticipated disease
With the notable increase of scientific, medical and commercial interests 
in the alleged properties of umbilical cord blood stem cells11 (one of the 
areas that has most rapidly multiplied in the private sector), biobanks have 
10 Government participation in R&D expenditure in Argentina was 77% versus 16.4% 
by public and private companies. The average for Latin America is 59.1% and 36.7%, 
respectively (RICYT, 2017).
11 Since the late 1980s, umbilical cord blood has been perceived as a valuable source of 
hematopoietic progenitor cells, considered an alternative source for bone marrow and 
peripheral blood in the treatment of various hematological diseases. Degenerative diseases 
of the nervous system are presented as an attractive target for therapy with cord stem cells.
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started to offer new options for the collection, processing and storage of 
cord blood and placenta stem cells. These cells can be used for potential 
autologous use and direct family use (Guardar células madre…, 2011). 
Seven main institutions provide this service, currently grouped in a 
single association. Storing umbilical cords in a private bank costs between 
1000 to 1500 USD and a 100-180 USD yearly fee as a maintenance service 
(Garau, 2015; Células madre: buscan regularlas…, 2018). In 2015 it was 
estimated that 10,000 people per year decide to keep umbilical cord 
tissues to prevent future emergencies with a trend of 15% annual increase 
(Garau, 2015). 
The over-optimistic coverage about the potential of umbilical cord 
blood stem cells storage for autologous use and stem cell therapies has been 
promoted by private stem cell banks and widely disseminated by the press 
(Guardar células madre…, 2011; Hartman, 2017). The advertisements of 
these institutions have become available at gynecological clinics, medical 
centers’ websites, as well as maternity and health publications, appealing 
to the individual responsibility of new parents on the future health of their 
children. They also refer to the unique timing of childbirth for ensuring 
access to these cells, which can then (reportedly) protect the newly born 
child in the future. Discourses sustained by these actors emphasize its 
use for the treatment of diseases such as leukemia, metabolic diseases, 
cartilage and bone regeneration and heart failure. These companies affirm 
the utility of cellular material storage on the assumption of its potential use 
for therapeutic applications. 
Parents are assigned the “responsibility” to make a decision that would 
(potentially) protect their children’s health12. This decision is of a preventive 
nature: these initiatives advertise an “opportunity” to be prepared for the 
“medicine of the future” (Krmpotic, 2011) and for potential (still unknown) 
12  Biobanks refer to this “responsibility” with advertising copies such as “Always at the 
forefront to help you protect what you most love”, “Take the most important decision for 
your child’s future today: keep the cells”, “Developing tools for regenerative medicine and 
for the future of who you most love” (Bortz et al., 2017).
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risks. Since umbilical cord blood or placenta storage does not guarantee 
subsequent access to treatments, keeping stem cells from cord blood 
appears as an uncertain technological alternative for an uncertain problem. 
The coalition sustained by the MSTPI, scientists, bioethicists, patient 
organizations, the Cord Blood Public Bank, and regulatory authorities warn 
against these services. In the controversy over the modes and criteria for 
storage and use of cellular material (public or private), the ACCTRM, warns 
against the risks of private banks, which “perform misleading propaganda 
by exalting the curative potentials in several diseases when there is still no 
clinical evidence for it”, given that any use of umbilical cord blood stem 
cells, other than bone marrow transplantation, is experimental (ACCTRM-
MSTPI, 2009b). 
The Cord Blood Public Bank of the Garrahan Children’s Hospital13 
shares this position. The bank reinforces a conception of cellular material as 
a public good and a “solidarity” system for donation and use14 (Stekolschik, 
2008; Hartman, 2017). However, despite the official position on this issue, 
the regulation on the subject, which is still recent, has not managed to place 
too many restrictions on the supply of such services and attempts made for 
regulation have not thrived as law (Krmpotic, 2011).
The supply of experimental treatments
The supply of clinical stem cell interventions without systematic testing 
and oriented towards commercial purposes has multiplied worldwide, to 
the extent that some authors have characterized it as the emergence of a 
13 The Public Cord Blood Bank of Pediatric Garrahan Hospital, created in 2005, is part of the 
international network Bone Marrow Donors Worldwide.
14 Among the arguments that support this stance are: (a) the uncertainty about the duration 
of cryopreserved cord cells; (b) the possibility of using own hematopoietic stem cells in case 
of need; (c) the recommendation not to use the patient’s own stem cells to treat a cancer or 
immune disorder, being only advisable to store the blood of a child when there is another 
child in the family who has or has had one of the diseases that can be treated with bone 
marrow transplantation, and even so, scientist sustain that there is only a 25% chance of 
compatibility.
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“global industry” of experimental stem cell interventions (McMahon, 2014). 
It is estimated that since the year 2000, several hundred thousand patients 
have received stem cells experimental treatments, offered at prices ranging 
from 5,000 to 50,000 USD, and up to 100,000. 
In Argentina, the ACCTRM-MSTIP appraises that around ten institutions 
are offering treatments in Argentina that have not undergone clinical trials, 
framed as professional “medical practices”. They supply from esthetic 
interventions to stem cell autotransplant treatments for brain or spinal 
cord injuries, neurodegenerative and metabolic diseases (ACCTRM-MSTIP, 
2009c; Grippo, 2013). There are also representatives from clinics based in 
other countries –mainly China and United States (Ferreras, 2012) – offering 
medical tourism services to patients with orphan or incurable diseases, or 
with minimal healing expectation.
These practices gained resonance with stem cell media coverage, 
having great influence on public opinion and patient individual decisions. 
This includes news about the “healing capacities” of stem cell therapies to 
charitable campaigns to raise funds to help ill children to afford their costs 
(Ferreras, 2012; Grippo, 2013; Furor solidario…, 2014).
The growing supply of these treatments has also affected local health 
systems. The refusal of private health insurances and public healthcare 
services to finance these treatments resulted in lawsuits and requests for 
legal protection from various patients. Between the lack of specificity of 
the current regulatory system and the demands of desperate patients, some 
judges have decided in favor of patients and forced public and private health 
services to cover experimental treatments (Arzuaga, 2013; Las prepagas…, 
2011). In other cases, the refusal of health care systems has led to the 
above-mentioned charitable fundraising campaigns.
Patients play a notable role in this “tissue economy”. They become 
acquainted with experimental treatments through recommendations from 
friends or relatives, website searches, discussion forums, referral from other 
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medical practitioners, driven by the pressing character of their ailments. 
The demand for experimental treatments in Argentina does not appear 
as “organized hope” but rather as individual quests based on the belief in 
cure, which often weighs stronger than scientific, political or legal evaluation 
(Krmpotic, 2011). It remains a personal and private negotiation between the 
pressure of the ailment and the risk of the treatment. The results of these 
interventions range from testimonies that indicate improvement to claims 
and lawsuits for deception and fraud due to ineffectiveness, unwanted 
effects or even death (Krmpotic, 2011; Grippo, 2013).
Against this backdrop, the coalition aligned by the MSTPI (which 
includes scientists, health regulatory authorities, bioethicists and the Public 
Blood Cord Bank), gathered in the advisory committee on cell therapies, 
discussed the problem of hyped expectations and healing promises among 
patients by the media, private cord banks, and clinics. 
The ACCTRM published numerous press releases, specifying the 
approved treatments (transplantation of bone marrow stem cells, peripheral 
blood and umbilical cord and autotransplantation of bone marrow and 
peripheral blood stem cells to treat blood diseases) and warning against 
the uptake of other treatments without appropriate evidence of safety and 
efficacy (ACCTRM-MSTPI, 2009a; 2009c; 2012). Unlike the biobanks, which 
frame “risk” as the future in which we can all be potentially sick, actors 
gathered at the ACCTRM focused on present biosafety risk of therapies that 
do not meet the criteria of evidence-based medicine. They also refer to 
the economic imbalance of these treatments for the public health system 
(Arzuaga, 2013).
This stance also aligns with the strategy of local patient organizations. Far 
from advocating for deregulation or the creation of regulatory alternatives to 
access experimental treatments, many organizations have raised awareness 
on the diseases and the risks of experimental therapies; denouncing 
the construction of “unreasonable expectations” from media coverage 
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(“Levántense y anden”, 2015) and advising patients who seek for these 
alternatives (De Santo, 2014). 
The Argentine Federation of Rare Diseases, which groups over 30 
member associations and patients groups15, leads these initiatives. Under 
the auspices of the MSTIP, the Federation and the ACCTRM launched the 
Argentine Network of Patients for Advanced Therapies (APTA Network) 
in 2013. This network provides a space for dialogue among scientists, 
regulators and organized patients. The creation of this network also involved 
the advice and support of the Genetics Policy Institute, which helped 
defining objectives to help Argentine patient groups to organize as a national 
network and to “create critical mass” (FADEPOF, 2013). The network’s 
aims were to coordinate efforts, raise awareness about cellular therapies, 
promote legislation, position this issue on the public agenda and inform 
patients and their families about advances in stem cell research and the 
risks of experimental treatments (FADEPOF, 2014). The APTA Network 
has established links with research groups, funding agencies, regulatory 
bodies, international patient advocacy groups and other relevant actors, 
and it aims at strengthening the voice of patients in the field of advanced 
therapies (FADEPOF, 2013).
Allied with scientists from Argentina and abroad, and mobilizing 
scientists, authorities and resources, patient organizations have begun 
generating local records of pathologies, setting up medical histories, building 
international databases and further ties with international patient groups. 
They advocate the development of new studies validated through clinical 
trials: trials that are approved by the competent regulatory authorities, with 
informed consent procedures, free to patients, and with detailed follow-
up of patients and possible future complications (FADEPOF, 2013; 2014).
15 The network gathers patient organizations on Scleroderma and Raynaud, Neurofibromatosis, 
Wilson’s disease, Primary Immunodeficiency, Parkinson’s disease, Psoriasis, Myeloid 
Leukemia, Alzheimer’s, Huntington disease, Ataxias, Amyotrophic Lateral Sclerosis, 
Thalassemia, Crohn’s Disease, among others.
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Regulation: the strive to govern innovation pathways
In Argentina, the process of building a specific regulatory framework 
for stem cell and advanced cellular therapies is still in the making. 
Legislation on the subject include the Medicines Act (1964), the 
Professional Practice of Medicine Act (1967) and the Transplant Act (1993). 
More recently, in 2007, the Argentine Ministry of Health issued the Ministerial 
Resolution 610/2007 for clinical use of stem cells in Argentina. This resolution 
states that the use of human cells comes under the authority of the Unique 
Central Institute for Ablation and Implantation (INCUCAI)16. By coming under 
the authority of INCUCAI, stem cell interventions are not regarded as a 
medical product (as in the EU, USA and India), but as a medical procedure, 
managed by the Argentine Transplant Act. 
Decree 512/95 specified that, with the exception of hematopoietic 
cell transplants from human bone marrow, all types of stem cells should be 
considered experimental and subject to evaluation of safety and efficacy 
through clinical research (Arzuaga, 2013; Harmon; Kale, 2015). New 
experimental practices require authorization of INCUCAI for research 
protocols17. A subsequent resolution issued by INCUCAI stipulated a technical 
standard to establish requirements and procedures for the preparation of 
16 Since 2001, the INCUCAI has been appointed as the organism in charge of the National 
Donor Registry of Hematopoietic Progenitor Cells (HPC) (Act 25.392/2001 and INCUCAI 
Res. 319/2004). In subsequent resolutions, the institute was the one to establish the 
classification of medical indications for autologous or allogeneic transplantation of HPC 
(Res. 307/2007), the procedures for tissue banking, including the banking of stem cells from 
umbilical cord blood (UCB) and regulating the activity of UCB banks (Res. 069/2009).
17 Subsequent dispositions by the health authorities have regulated on good clinical research 
practices, including requirements of informed consent of research subjects, approval 
by ethics committees, and gratuity in the participation in the procedures (e.g. ANMAT 
Dispositions 5330/1997 and 6677/2010). The new Nation’s Civil and Commercial Code 
(Law 26.994/2014) incorporated in 2014 “Personal Rights and Acts” (Chapter 3), regulating 
through Art. 58 research in human beings. It prescribes the need of clarity in project 
formulation, professional qualifications, approval by ethics committees, authorization 
by public agencies, risk assessment, informed consent, protection of intimacy, gratuity of 
participation in clinical research, among others.
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cellular products (Resolution 19/2012), aligned with international standards 
of good laboratory and manufacturing practices (Arzuaga, 2013).
In the late 2000s, a dispute emerged among Argentina’s regulators 
whether stem cells should be regulated as a medical product instead. This 
entails not only a matter of political governance but also the need of new 
therapies to undergo Phase I-III clinical trials for their approval. As a result, 
Argentina’s National Administration of Drugs, Food and Medical Technology 
(ANMAT) started to play a major role in regulating the use of stem cells. 
A first step in this direction was achieved in 2011 by ANMAT regulation 
7075 that sets the general requirements for market approval of biological 
drugs. More than minimally modified cellular products were classified as 
advanced therapeutic medicinal products (ATMP), together with gene 
therapy and tissue-engineered products. This follows the “cells-as-drugs” 
approach of the United States and the European Union which is enforced 
through the Regulation for Human, Cellular and Tissue Products (HCT/Ps) 
in the USA, and the Advanced Therapy Medicinal Products (ATMP) in the 
EU, both issued in 2007. These regulatory approaches frame stem cells 
as a product and establish a risk-based distinction between (i) minimally 
manipulated stem cells for autologous use, and (ii) more than minimally 
manipulated stem cells for allogeneic use. While the former come under 
the human tissue regulation and do not require prior approval by health 
authorities, the latter become subject to prior approval by the respective 
drug regulatory agencies (Rosemann et al., 2016). 
During 2017 and 2018, an interministerial workgroup that included 
professionals from both the Ministry of Health and the Ministry of Science, 
Technology and Innovation was created (Joint Res.-E1/2017). It aimed to 
clarify the competencies of ANMAT and INCUCAI and draft better regulations 
in the area (Células madre: buscan regularlas…, 2018).
As a result, a specific regulation on ATMPs (ANMAT 179/18) was issued 
in September 2018. This rule includes more specific definitions of the 
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products that fall within the ATMPs subcategories of cellular therapy, gene 
therapy and tissue-engineered products. In addition, it provides a clearer 
guidance on the role and legal competencies of INCUCAI and ANMAT. 
The former will be responsible for regulating the donation, obtention and 
verification of cellular tissue. In turn, ANMAT will oversee the production, 
registration, approval and surveillance of ATMPs. The manufacturing site 
will have to follow manuals of Good Manufacturing Practices and clinical 
trials will have to comply with the same Good Clinical Practice guides that 
apply to all clinical research.  It is expected that INCUCAI will issue shortly 
specific regulations for the stages of ATMP development that fall within its 
competence. The two agencies are expected to work in a more coordinated 
fashion in the future. 
However, the current legal reach of both INCUCAI and ANMAT is 
limited. Argentina is a federal country in which national regulatory authorities 
have legal power only when medical products cross provincial borders or are 
involved in foreign trade. As a result, national regulations are not applicable 
at the provincial level when medical procedures are applied exclusively 
within the provincial jurisdiction (Arzuaga, 2013). This also leaves room 
for situations where treatments are manufactured and provided to patients 
completely within a single health facility, so-called “hospital exemptions”. 
The current state of the regulatory framework opens a grey area for 
the provision of experimental treatments outside evidence-based medicine, 
within a de facto “governance vacuum” (Sleeboom-Faulkner; Patra, 2008; 
McMahon, 2014). While unproven treatments are framed as professional 
medical procedures, and those procedures remain within their own local 
jurisdiction, authorities are inhibited to act ex-officio. This is the main concern 
of regulators and the new rules that are being drafted aim to narrow down 
this grey area. With that end, the ACCTRM announced that a new specific 
bill is being drafted by the Health-STI interministerial workgroup, and 
expected to be filed in 2019 (Células madre: buscan regularlas…, 2018).
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Two likely persisting restraints on the new regulation will be, firstly, 
the problem on establishing a punitive system on medical professionals, 
bypassing local collegiate associations. Secondly, the persistence of a legal 
vacuum on the registration and control of private umbilical cord blood 
banks (Hartman, 2017).
For the STI authorities, configuring a regulatory framework to govern 
stem cell clinical research and treatments has been considered a priority 
action for over a decade (MSTPI, 2012), along with an intense capacity 
building program. In the regulatory choice process, heterogeneous local 
stakeholders gathered around the stance that flexible standards affect the 
credibility of locally developed stem cell therapies within the global market, 
rejecting the assumption that rapid market approval may generate higher 
domestic economic benefits. Therefore, national investment was directed 
towards R&D activities that might be of greater value in the long term, 
oriented towards the global market.
The current state of regulatory shaping shows a large coalition, supported 
by the ACCTRM, which aligns the MSTPI, scientists, bioethicists, patient 
organizations, doctors, the Cord Blood Public Bank, the Ministry of Health, 
ANMAT, INCUCAI and, on an international level, the ISSCR and foreign 
regulatory agencies. This coalition converged on defining the object of 
regulation as a product (a biological drug) – foreseeing differences related 
to levels of cell manipulation –, and the regulatory purpose to “ensure the 
safety, quality and efficacy of the products and treatments that are prescribed 
to patients” (MSTPI, 2016). To that end, capacity building, in scientific and 
regulatory terms, is seen as a requirement to reach global standards.
The national orientation on stem cells has leaned towards regulatory 
harmonization with international standards, compatible with the United 
States and Europe. These provisions involve extensive preclinical evidence, 
the use of Phase I-III clinical trials and international good practice standards. 
This direction enables the participation of potential Argentine stem 
cell products in the global market while it raises the entry barriers for 
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researchers and Argentine biotech companies. It may also provide more 
reliable knowledge about the safety, quality and efficacy of new treatments, 
safeguarding patients. However, there are questions that still remain to be 
answered. For instance, what are the local funding capacities to sustain 
long-drawn-out multi-stage clinical trials? Do the productive capacities to 
manufacture and commercialize these national developments exist? What 
are the social expenditure capacities to include these therapies within 
collective health systems?
Conclusions
For the past decade, Argentine STI policy makers and scientists have 
considered stem cell technologies a window of opportunity for national 
positioning at the technological frontier, participating in a global R&D 
dynamic since its early stage. To that end, they deployed institutional, 
regulatory and financing actions to build endogenous capacities in the area, 
according to international standards. 
We have analyzed technology regulation as an essential feature in 
the adoption of national strategies, aiming to embed visions into desired 
technology paths and to shape how these emergent technologies are/will 
be produced, accessed and used. The configuration of a specific normative 
framework creates (an at least temporary stage of) closure and favor one 
technology option over others. It does so by defining the object and by 
establishing standards for safety, efficacy and risk, as well as acceptable 
processes and legitimized actors and procedures. Stem cell regulation in 
Argentina has been a long-standing process that is still in the making. As 
part of this process, a heterogeneous coalition emerged that aligned the STI 
sector with bioethicists, regulators, health authorities, patient organizations, 
and public cord biobanks, among others. These efforts were met with 
opposition by another (more diffused) stakeholder coalition, which comprised 
private stem cell clinics that supply treatments, private cord blood banks, 
individual patients, soon-to-be parents’ forums and mass media, spreading 
un-evidenced expectations on this technology.
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Building on previous works, this paper also aimed to position the 
Argentine case within global regulatory trends for stem cell medicine. Since 
the early 2000s, Argentine STI authorities adopted an official stance that 
aligned with harmonization trends led by the regulatory agencies of the 
United States, the European Union and the ISSCR. Although some regulatory 
initiatives that aimed to broaden access to investigative medicines were 
adopted by regulators in Argentina (such as a compassionate use program), 
the country’s position remains under the paradigm of evidence-based 
medicine and the use of multi-stage, randomized clinical trials (RCT) as 
methodological gold standard. This diverges from other developing countries 
such as China and India, which allowed for a more flexible enforcement 
of regulatory standards that enabled the toleration of non-systematically 
proven, experimental for-profit therapies with stem cells for many years. 
Moreover, the abandonment of RCTs and the introduction of early stage 
conditional market approval which could be observed in Japan, seems 
unlikely to happen in Argentina.
The persistence of legislative loopholes and ambiguities, the 
characteristics of the federal Argentine system, and the soft enforcement 
capacities of the agencies generated a legal ‘grey area’ for the supply of 
experimental unproven treatments. ANMAT regulation 179/18 on ATMPs 
and the forthcoming INCUCAI rule are expected to tackle this situation 
and limit the availability of experimental treatments outside the multi-phase 
clinical trial pathway.   
In the second section, we sketched four tensions linking regulation 
with national innovation strategies: 
(a) International integration to global markets vs. domestic innovation 
business opportunities. This opposition appears as false to Argentine 
authorities, under the policy belief that an alternative regulatory framework 
will not foster domestic stem cell innovation and competitiveness. Given a 
small internal market for these therapies, national strategies were oriented 
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from the start with a global export scope, requiring harmonized standards 
for research and product development. 
(b) Rapid and early development vs. systematic testing. The coalition 
supporting stem cell technology policy in Argentina has clearly aligned 
with the second stance. However, even when local basic research is taking 
place at the technological frontier, the capabilities and resources to enable 
clinical translation through RCTs are still at an early stage. In order to change 
this situation, new administrative capacities are required to guide clinical 
testing. But above all, financial and infrastructure capacities are required 
that enable national laboratories and firms to conduct Phase I-III systematic 
testing, so that compliance with international standards (as required by 
Argentina’s regulatory authorities) can be achieved. 
To date, most stem cell research has been conducted with public 
funding. The availability of private financing for innovation in Argentina 
is limited (from either companies or investment funds). The effective 
possibility of locally developed products accessing the domestic and global 
market requires more than R&D grants. It necessitates the availability of 
sound funding to meet the costs of expensive RCTs, in a context where 
the effectiveness of candidate therapeutic applications is still uncertain. 
(c) Affordable medicines vs. corporate profits. At present, the discussion 
on the accessibility and affordability of new medicines relates especially 
to the topic of free access to clinical trials, as opposed to the provision of 
for-profit treatments in clinics, which has been rejected by local authorities. 
Concerns have also been raised on court rulings that compelled the health 
system and insurance companies to cover untested procedures, diverting 
resources that could be used for other ends. However, the issue on how 
stem cell technologies could in the future be made accessible for most of 
the population (an aspiration that is promoted by some scholars and policy 
makers (Greenwood et al., 2006) and become integrated into national health 
systems, has not yet entered the public discussion and remains unclear. STI 
policy follows – once again – a linear science-driven innovation model; 
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placing the construction of social utility at the end of the range of concerns 
of scientific practices. 
(d) State led regulatory control vs. deregulation demands. Argentina’s 
ambitions of stem cell technology is clearly led by the state, in a co-production 
process that has involved biomedical scientists and STI authorities and aligned 
other heterogeneous actors around this issue, both at the level of capacity 
building and regulation formation. On the other end of the spectrum, there 
is no organized demand for deregulation. Rather, one witnesses diffused 
actors working within the grey spaces of the legislation. 
Stem cell research, clinical testing, production and marketing in 
Argentina still appears to have a long way to go. The construction of this 
field as a desirable technological future has focused on R&D promotion and 
the prevention of unproven treatments. But the possibilities of conducting 
Phase I-III clinical trials and marketing these therapies with a global reach 
would require a more comprehensive approach. At present, local regulatory, 
production, and financial capabilities still do not facilitate this process. 
At the same time, considering the pressing problems the country faces 
in terms of ensuring people’s access to basic goods and services (food, 
water and sanitation, housing, energy, access to health services, quality 
education, communication infrastructure), it is by and large, debatable if 
it is the State that should provide for such an increased outlay. This opens 
a new discussion on what goes beyond stem cell R&D, and beyond tracing 
a new national strategy (and aligning new elements) to build the utility of 
this technology – as a strategic technology and not only a research priority 
– beyond laboratory walls and with concrete social benefits.
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